Fig. 2: Discovery—molecular assessments and trial arm allocation.

a–f, SOC (TMZ; a), arm A (asunercept; b), arm C (idasanutlin; c), arm D (atezolizumab; d), arm F (palbociclib; e) and arm G (temsirolimus; f) are shown. amp, amplified; del, deleted; mut, mutated; MES, mesenchymal.